Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy Virtual 2020 | Saad Usmani: BELLINI, CANDOR, ICARIA-MM and CAR-T

Saad Usmani • 14 May 2020
COMy Virtual 2020
Multiple Myeloma bb21217 Bortezomib Carfilzomib Daratumumab Idecabtagene vicleucel Isatuximab Venetoclax

Saad Usmani, MD, FACP, Levine Cancer Institute & Atrium Health, Charlotte, NC, discusses the optimal choice of therapy beyond first relapse in multiple myeloma. The BELLINI, CANDOR and ICARIA-MM trials (NCT02755597, NCT03158688, NCT02990338) are discussed, as are CAR-T cell approaches to therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Saad Usmani

The value of iwHRMM and wrap-up of the 2025 meeting 2:23
The value of iwHRMM and wrap-up of the 2025 meeting
Saad Usmani • 24 Oct 2025
Myeloma updates from EHA 2022: the DETERMINATION trial, the role of transplant, and exciting novel immunotherapies
Mohamad Mohty et al. • 15 Jul 2022
iwGPRC5D 2025: highlights from the workshop 2:44
iwGPRC5D 2025: highlights from the workshop
Saad Usmani et al. • 22 Mar 2025
Bispecific antibodies in the treatment of HRMM: optimizing therapy and combination strategies
Ajai Chari et al. • 4 Nov 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals